Amebiasis market seen growing to $1.2 billion by 2030
The global amebiasis market is projected to rise from $0.88 billion in 2025 to $1.2 billion by 2030, according to The Business Research Company. Growth is tied to poor sanitation, limited clean water, rising parasitic infections and demand for better diagnostics and targeted antiparasitic therapies.
Why it matters: - Amebiasis is linked to unsafe water and sanitation conditions that remain widespread across the world. - The market’s growth reflects both persistent disease burden and expanding access to diagnosis and treatment, especially in developing regions. - Better antiparasitic therapies and diagnostics could improve outcomes and reduce transmission.
What happened: - The Business Research Company released its Amebiasis Global Market Report 2026 on Oct. 30, 2026. - The report projects the amebiasis market will grow from $0.88 billion in 2025 to $0.93 billion in 2026. - The report forecasts the market will reach $1.2 billion by 2030. - The forecast implies a 6.4% compound annual growth rate over the forecast period. - North America held the largest share of the market in 2025. - Asia-Pacific is expected to grow the fastest through the forecast period.
The details: - Amebiasis is an intestinal illness caused by the parasite Entamoeba histolytica. - Common symptoms include diarrhea and abdominal cramps. - Severe cases can lead to liver abscesses. - Treatment usually includes metronidazole and tinidazole. - The report ties recent market growth to poor sanitation, limited access to clean water, metronidazole-based treatment use, public health initiatives and generic antiparasitic drugs. - Future growth is linked to investment in infectious disease management, demand for better diagnostic technologies, broader healthcare access in developing countries, antimicrobial resistance efforts and targeted antiparasitic therapies. - Emerging trends include combination drug treatments, earlier diagnosis, growth in oral antiparasitic drugs, greater awareness of waterborne illness and improved access to essential medicines. - The report says increasing parasitic infections are a major driver of the market. - In February 2025, the CDC reported about 100 million amebiasis infections worldwide each year, mainly in developing regions. - The CDC said about 90% of those cases are asymptomatic but still contribute to community spread. - UNICEF said in March 2023 that about 3.6 billion people lack safely managed household sanitation. - UNICEF also said 1.8 billion people lack access to safe drinking water. - UNICEF estimated 829,000 deaths annually are linked to unsafe water, poor sanitation and inadequate hygiene. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company said 2026 report updates include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The report offers a free sample and a full market report at More information and the full report.
Between the lines: - The market outlook suggests steady demand rather than a sharp surge, with a modest slowdown from 6.6% growth in 2025-2026 to 6.4% through 2030. - The biggest demand drivers are structural, not cyclical, because sanitation gaps and clean-water shortages are still fueling infection risk. - The emphasis on diagnostics and combination therapies points to a market moving toward earlier intervention and more targeted treatment.
What's next: - Market growth is likely to track public health investment, sanitation improvements and adoption of newer treatment approaches. - Asia-Pacific’s faster growth could reflect expanding healthcare access and higher disease burden across the region. - The report’s focus on antimicrobial resistance and diagnostic innovation suggests those areas may shape product development and market competition next.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Global Finance Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.